First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025.
COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA® for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older.
The virus-like particle (VLP) single-dose vaccine is the first chikungunya vaccine approved in Europe for persons as young as 12 years old. The approval, valid in all EU member states, as well as in Iceland, Liechtenstein, and Norway, marks the second approval of VIMKUNYA, following the approval by the U.S. Food and Drug Administration (FDA) earlier this month. Bavarian Nordic also recently submitted a Marketing Authorization Application (MAA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA) with potential approval of the chikungunya vaccine in the UK in the first half of 2025.
Bavarian Nordic will launch VIMKUNYA in key European markets in the first half of 2025.
“We are highly encouraged by the European Commission’s accelerated decision to approve our chikungunya vaccine in Europe, which offers a differentiated profile for travelers, including those as young as 12 years,” said Paul Chaplin, President and CEO of Bavarian Nordic. “As we expand our presence across Europe, this vaccine will help to further consolidate our leading position in travel vaccines, and we look forward to making the vaccine available in key markets during the first half of 2025.”
The marketing authorization was granted by the European Commission upon recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in January 2025 and was based on results from two phase 3 clinical trials which enrolled
